Survodutide vs Retatrutide: How the Two Weight Loss Drugs Compare

Survodutide and retatrutide are both investigational, once-weekly injectable weight loss drugs, but they are not interchangeable. Survodutide is a dual GLP-1 and glucagon receptor agonist from Boehringer Ingelheim and Zealand Pharma, while retatrutide is a triple GLP-1, GIP, and glucagon agonist from Eli Lilly. Neither drug is FDA-approved for human use in the United States, and retatrutide has produced larger average weight loss in mid-stage trials.

What Is Survodutide?

Survodutide, also known as BI 456906, activates GLP-1 and glucagon receptors at the same time. The GLP-1 arm suppresses appetite and slows stomach emptying, while the glucagon arm is thought to raise energy expenditure and act directly on liver fat.

Boehringer Ingelheim is running the Phase 3 SYNCHRONIZE program in obesity, type 2 diabetes, and cardiovascular outcomes, plus a separate Phase 3 effort in MASH, a fatty liver disease.

• Phase 2 obesity result: roughly 14.9% average weight loss at 46 weeks on the 4.8 mg dose
• Phase 2 MASH result: up to 83% of participants reached at least a 30% relative reduction in liver fat
• Administration: once-weekly subcutaneous injection

What Is Retatrutide?

Retatrutide (LY3437943) is a triple agonist that targets GLP-1, GIP, and glucagon receptors at once. Eli Lilly developed it as a next step beyond tirzepatide, which hits only GLP-1 and GIP.

In a Phase 2 trial published in the New England Journal of Medicine, participants on the 12 mg dose lost an average of about 24.2% of body weight over 48 weeks. That remains the largest average weight reduction reported for an investigational obesity drug in a mid-stage trial.

Lilly's Phase 3 TRIUMPH program is testing retatrutide in obesity, obstructive sleep apnea, knee osteoarthritis pain, and type 2 diabetes.

Survodutide vs Retatrutide at a Glance

Feature	Survodutide	Retatrutide
Developer	Boehringer Ingelheim / Zealand Pharma	Eli Lilly
Receptor targets	GLP-1 + glucagon	GLP-1 + GIP + glucagon
Route	Weekly injection	Weekly injection
Highest trial phase	Phase 3	Phase 3
Phase 2 weight loss	About 14.9% at 46 weeks (4.8 mg)	About 24.2% at 48 weeks (12 mg)
Lead indications	Obesity, MASH, type 2 diabetes	Obesity, sleep apnea, knee OA, type 2 diabetes
FDA status	Not approved	Not approved

Survodutide has the deeper liver-disease data package, while retatrutide holds the stronger headline weight loss numbers. Both remain strictly investigational.

How the Mechanisms Differ

The extra GIP receptor is the biggest mechanistic gap between these two drugs. GIP appears to improve insulin handling and may soften some of the nausea that GLP-1 drugs cause, which helps explain why triple agonists can be pushed to higher effective doses.

Glucagon receptor activation is the shared wild card. Turning on glucagon normally raises blood sugar, but when paired with strong GLP-1 signaling, the net effect in trials has been weight loss and reduced liver fat rather than hyperglycemia.

Weight Loss Results: Read the Numbers Carefully

Retatrutide's 24.2% figure is higher than survodutide's 14.9%, but those numbers come from separate trials with different doses, titration schedules, populations, and durations. Cross-trial comparisons are not proof that one drug is better.

A few details matter when interpreting the data:

• Both trials measured weight loss at roughly 46 to 48 weeks, not at the 68 to 72 weeks typical of Phase 3 obesity studies.
• Survodutide's headline number reflects the 4.8 mg dose, and optimized titration could shift that result.
• Retatrutide's 8 mg and 12 mg arms both exceeded 20% average weight loss, suggesting a wide therapeutic window.
• Survodutide's MASH data give it a possible edge in liver disease, an area where retatrutide has published less.

How Retatrutide Stacks Up Against Other Contenders

Retatrutide is far from the only molecule competing in this space. People researching it often end up comparing it with a broad field of injectable and oral candidates.

• Mazdutide vs retatrutide: mazdutide is a GLP-1 and glucagon dual agonist approved in China for weight management, but it is not authorized in the US and has shown smaller average weight loss than retatrutide.
• CagriSema vs retatrutide: CagriSema pairs cagrilintide with semaglutide, an amylin plus GLP-1 combination rather than a triple agonist. Novo Nordisk reported roughly 22.7% average weight loss at 68 weeks in REDEFINE-1.
• Orforglipron vs retatrutide: orforglipron is Eli Lilly's oral, non-peptide GLP-1 pill. It is far more convenient than an injection but has produced less weight loss.
• Eloralintide vs retatrutide: eloralintide is a once-weekly amylin analog that may eventually be used alone or stacked with incretin drugs.

Combination and comparator questions come up constantly in this field, which is why searches for cagrilintide vs retatrutide vs tirzepatide keep climbing. The same pattern shows up with cagrilintide vs retatrutide, since amylin-based drugs work through a completely different pathway than triple agonists.

Side Effects and Safety

Both drugs belong to the incretin family, so they share a similar side effect profile: nausea, vomiting, diarrhea, constipation, reduced appetite, and injection-site reactions. These effects are usually worst during dose escalation.

Retatrutide's Phase 2 trial also reported paresthesia, a tingling or altered skin sensation, in a small share of participants, a signal that has not appeared with survodutide. Survodutide trials have monitored liver enzymes because of its glucagon component.

Neither drug should be used outside a clinical trial. Anyone considering an incretin medication should talk with a licensed healthcare professional about approved options and personal risk factors, including a history of pancreatitis, gallbladder disease, or medullary thyroid cancer.

Other Peptides People Confuse With These Drugs

Not everything marketed as a weight loss peptide belongs in the same conversation. Some compounds circulating in research and fitness circles work through entirely different biology.

Growth-hormone-releasing peptides such as tesamorelin are sometimes pulled into the debate through tesamorelin peptide vs retatrutide searches, even though tesamorelin is FDA-approved for lipodystrophy in people with HIV and works on the GH axis, not on incretin receptors.

Fat-metabolism research peptides are a separate lane too. Comparisons such as aod 9604 vs mots-c focus on lipolysis versus mitochondrial signaling, and community threads sometimes mention aod 9604 and retatrutide in the same breath even though the two have never been studied together. Unrelated categories get tangled in as well, including pt-141 nasal spray vs injection discussions in sexual-health research.

Bottom Line

Retatrutide has produced the larger average weight loss in trials so far, about 24.2% at 48 weeks, while survodutide brings stronger liver-fat data and a dual-agonist design. No head-to-head trial has compared the two directly.

Patients interested in either option should enroll in a clinical trial or wait for FDA review rather than buying unverified peptides online. Approved alternatives such as semaglutide and tirzepatide remain the only regulated, evidence-based choices available today.

COMMON QUESTIONS

Frequently Asked Questions

Is retatrutide better than survodutide for weight loss?

In separate Phase 2 trials, retatrutide produced greater average weight loss, about 24.2% at 48 weeks on the 12 mg dose, compared with roughly 14.9% at 46 weeks for survodutide at 4.8 mg. However, these were different studies with different doses, designs, and patient populations, so the numbers cannot be compared directly. Survodutide has stronger published liver-fat data in MASH.

Are survodutide and retatrutide FDA approved?

No. Both survodutide and retatrutide are still investigational and are not approved by the FDA for weight loss or any other indication in the United States. They are currently available only through clinical trials. Approved GLP-1 options such as semaglutide and tirzepatide remain the regulated choices on the market.

What are the most common side effects of survodutide and retatrutide?

Both drugs commonly cause gastrointestinal effects, including nausea, vomiting, diarrhea, constipation, and injection-site reactions, especially during dose increases. Retatrutide's Phase 2 trial also reported paresthesia, a tingling or altered skin sensation, in a small number of participants. Anyone with a history of pancreatitis, gallbladder disease, or medullary thyroid cancer should discuss these risks with a healthcare professional.